MA28991B1 - Procede pour concentrer des anticorps, et produits therapeutiques correspondants - Google Patents

Procede pour concentrer des anticorps, et produits therapeutiques correspondants

Info

Publication number
MA28991B1
MA28991B1 MA29809A MA29809A MA28991B1 MA 28991 B1 MA28991 B1 MA 28991B1 MA 29809 A MA29809 A MA 29809A MA 29809 A MA29809 A MA 29809A MA 28991 B1 MA28991 B1 MA 28991B1
Authority
MA
Morocco
Prior art keywords
therapeutic products
corresponding therapeutic
concentrating
antibodies
concentrating antibodies
Prior art date
Application number
MA29809A
Other languages
English (en)
Inventor
Charles Matthew Winter
Original Assignee
Genentech Inc
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35996499&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28991(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc, Novartis Ag filed Critical Genentech Inc
Publication of MA28991B1 publication Critical patent/MA28991B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C07K16/4283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig
    • C07K16/4291—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against immunoglobulins against an allotypic or isotypic determinant on Ig against IgE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • B01D61/146—Ultrafiltration comprising multiple ultrafiltration steps
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/16—Feed pretreatment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2311/00—Details relating to membrane separation process operations and control
    • B01D2311/16—Flow or flux control
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Water Supply & Treatment (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
MA29809A 2004-09-09 2007-04-06 Procede pour concentrer des anticorps, et produits therapeutiques correspondants MA28991B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60909204P 2004-09-09 2004-09-09
US11/220,362 US20060051347A1 (en) 2004-09-09 2005-09-06 Process for concentration of antibodies and therapeutic products thereof

Publications (1)

Publication Number Publication Date
MA28991B1 true MA28991B1 (fr) 2007-11-01

Family

ID=35996499

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29809A MA28991B1 (fr) 2004-09-09 2007-04-06 Procede pour concentrer des anticorps, et produits therapeutiques correspondants

Country Status (33)

Country Link
US (6) US20060051347A1 (fr)
EP (5) EP3805248B1 (fr)
JP (2) JP5210633B2 (fr)
KR (2) KR101528970B1 (fr)
CN (3) CN101056885B (fr)
AR (1) AR050641A1 (fr)
AU (1) AU2005285243C1 (fr)
BR (1) BRPI0515649B8 (fr)
CA (1) CA2577317C (fr)
DK (4) DK4108259T3 (fr)
EC (1) ECSP077282A (fr)
ES (3) ES2942574T3 (fr)
FI (2) FI3805248T3 (fr)
GT (1) GT200500254A (fr)
HK (2) HK1101249A1 (fr)
HU (2) HUE065025T2 (fr)
IL (2) IL181372A (fr)
LT (3) LT3805248T (fr)
MA (1) MA28991B1 (fr)
MX (2) MX2007002812A (fr)
MY (2) MY150549A (fr)
NO (1) NO333660B1 (fr)
NZ (1) NZ553239A (fr)
PE (1) PE20060816A1 (fr)
PL (4) PL4108259T3 (fr)
PT (4) PT3805248T (fr)
RU (1) RU2390524C2 (fr)
SG (1) SG177161A1 (fr)
SI (4) SI2292636T1 (fr)
TN (1) TNSN07069A1 (fr)
TW (1) TWI372630B (fr)
WO (1) WO2006031560A2 (fr)
ZA (1) ZA200701626B (fr)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60139944D1 (de) * 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
CA2554883C (fr) 2004-01-30 2013-10-01 Zymenex A/S Production et purification d'arylsulfatase a recombinante
EP1758558B1 (fr) 2004-05-12 2013-10-16 Baxter International Inc. Administration de microspheres d'oligonucleotides antisens pour induire une tolerance de cellules dendritiques pour le traitement du diabete de type 1 insulino-dependant
DE602005009954D1 (de) 2004-05-12 2008-11-06 Baxter Int Nukleinsäure-mikrokügelchen, ihre herstellung und abgabe
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
EP3673919A1 (fr) 2005-06-14 2020-07-01 Amgen Inc. Formulations de protéine à tamponnage spontané
DK2007506T3 (da) * 2006-03-31 2014-06-16 Danisco Us Inc Tangentialstrømningsfiltreringsapparater, -systemer og -fremgangsmådertil separering af forbindelser
JP2009532394A (ja) * 2006-04-04 2009-09-10 シャイア ファーマシューティカルズ アイルランド リミテッド ポリペプチドの濃縮方法
US8168760B2 (en) 2007-03-29 2012-05-01 Abbott Laboratories Crystalline anti-human IL-12 antibodies
CN101754977B (zh) * 2007-07-17 2013-07-17 弗·哈夫曼-拉罗切有限公司 可变切向流过滤
WO2009068282A1 (fr) * 2007-11-29 2009-06-04 F. Hoffmann-La Roche Ag Agrégats d'immunoglobulines
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
NZ602498A (en) * 2007-11-30 2014-08-29 Abbvie Inc Protein formulations and methods of making same
PL2271382T3 (pl) * 2008-04-15 2013-08-30 Grifols Therapeutics Inc Dwuetapowa ultrafiltracja/diafiltracja
BRPI0911994A2 (pt) * 2008-05-15 2015-10-20 Health L P W processo para a produção de uma fração de leite enriquecida com iga secretora, produto, e, composição.
CA2744510A1 (fr) * 2008-12-09 2010-06-17 F.Hoffmann-La Roche Ag Procede d'obtention d'une solution d'anticorps exempte d'excipient
WO2010090864A2 (fr) * 2009-01-21 2010-08-12 Smartflow Technologies, Inc. Optimisation de la séparation pour des suspensions visqueuses
EP2403874A1 (fr) * 2009-03-06 2012-01-11 Genentech, Inc. Formulation d'anticorps
JP6159528B2 (ja) * 2009-03-24 2017-07-05 ワイス・エルエルシー 高濃縮のタンパク質治療薬を生成するための膜蒸発
EP3708581A3 (fr) * 2009-05-27 2021-10-20 Takeda Pharmaceutical Company Limited Procédé pour produire une préparation d'immunoglobuline hautement concentrée pour usage sous-cutané
DK2483304T3 (en) * 2009-09-29 2016-05-30 Hoffmann La Roche FOR-FILTER ADJUSTING THE BUFFER SOLUTIONS FOR HIGH-CONCENTRATION-immunoglobulin
MX342442B (es) * 2009-10-01 2016-09-29 F Hoffmann-La Roche Ag * Filtracion final en multiples pasos.
WO2011095543A1 (fr) 2010-02-04 2011-08-11 Csl Behring Ag Préparation d'immunoglobuline
CA3101298A1 (fr) 2010-03-01 2011-09-09 Bayer Healthcare Llc Optimisation d'anticorps monoclonaux diriges contre l'inhibiteur de la voie du facteur tissulaire (tfpi)
EP2729566B1 (fr) 2011-07-08 2017-03-15 Shire Human Genetic Therapies, Inc. Procédés de purification d'arylsulfatase a
MY182178A (en) 2011-09-01 2021-01-18 Chugai Pharmaceutical Co Ltd Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration
WO2013096791A1 (fr) 2011-12-23 2013-06-27 Genentech, Inc. Procédé pour fabriquer des formulations de protéine à concentration élevée
US20130281355A1 (en) 2012-04-24 2013-10-24 Genentech, Inc. Cell culture compositions and methods for polypeptide production
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
JP2016504344A (ja) * 2012-12-28 2016-02-12 ノヴォ ノルディスク アー／エス 高温デッドエンド抗体ろ過
ES2768261T3 (es) 2013-01-09 2020-06-22 Shire Human Genetic Therapies Métodos para la purificación se arilsulfatasa A
DE102013001628A1 (de) 2013-01-30 2014-07-31 Fresenius Medical Care Deutschland Gmbh Verfahren zur Bereitstellung eines Konzentrats
IL285529B2 (en) 2014-05-13 2023-03-01 Amgen Inc Process control systems and methods for the use of filters and filtration processes
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
EP2957335B1 (fr) * 2014-06-16 2020-05-27 EMD Millipore Corporation Systèmes et processus de filtration monopasse
EP4144434B1 (fr) * 2014-06-16 2024-04-17 EMD Millipore Corporation Systèmes et procédés de filtration à passage unique
WO2015195453A2 (fr) * 2014-06-16 2015-12-23 Emd Millipore Corporation Procédés pour augmenter la capacité de processus à écoulement continu
US10399039B2 (en) 2014-06-25 2019-09-03 Emd Millipore Corporation Compact spiral-wound filter elements, modules and systems
CN108325391B (zh) 2014-08-29 2021-05-18 Emd 密理博公司 过滤液体进料的方法
SG10201901555UA (en) 2014-08-29 2019-03-28 Emd Millipore Corp Single Pass Tangential Flow Filtration Systems and Tangential Flow Filtration Systems withRecirculation of Retentate
AU2015335743B2 (en) 2014-10-23 2020-12-24 Amgen Inc. Reducing viscosity of pharmaceutical formulations
GB201506870D0 (en) 2015-04-22 2015-06-03 Ucb Biopharma Sprl Method
AU2016329034B2 (en) * 2015-09-22 2019-05-23 Pfizer Inc. Method of preparing a therapeutic protein formulation and antibody formulation produced by such a method
EP3950702A1 (fr) * 2016-08-16 2022-02-09 Genzyme Corporation Procédés de traitement d'un fluide comprenant une protéine thérapeutique recombinante et leur utilisation
CN118085011A (zh) * 2016-08-17 2024-05-28 勃林格殷格翰国际公司 制备含有生物分子的高度浓缩的液体制剂的方法
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
CN107952280A (zh) * 2017-11-28 2018-04-24 安徽东方帝维生物制品股份有限公司 一种兽用疫苗无菌超滤浓缩装置及方法
KR20190079530A (ko) * 2017-12-27 2019-07-05 (주)셀트리온 투석 여과 방법
AU2019250882A1 (en) * 2018-04-12 2020-11-05 Amgen Inc. Methods for making stable protein compositions
KR20210005237A (ko) * 2018-05-04 2021-01-13 젠자임 코포레이션 여과 시스템을 구비한 관류식 생물반응기
CN112702991A (zh) * 2018-08-10 2021-04-23 安进公司 制备抗体药物配制品的方法
CN112566920A (zh) * 2018-08-14 2021-03-26 百时美施贵宝公司 改善的蛋白质回收
TW202043253A (zh) * 2019-01-28 2020-12-01 美商安進公司 藉由將藥物物質和藥物產品過程整體化的生物製劑製造之連續製造過程
PL3791395T3 (pl) * 2019-07-31 2022-01-24 Catalent U.K. Swindon Zydis Limited Gęstościomierz przepływowy do dozowania formulacji farmaceutycznej
CN111018968B (zh) * 2019-12-16 2021-07-27 兴盟生物医药(苏州)有限公司 一种通过超滤浓缩制备高浓度抗体制剂的方法
JP7338527B2 (ja) * 2020-03-19 2023-09-05 東レ株式会社 体液検体中のアレルゲン特異的ＩｇＥ抗体の検出方法
CN111944046B (zh) * 2020-08-28 2021-04-09 江苏荃信生物医药有限公司 高浓度、低粘度抗人il-23单克隆抗体溶液的制备方法
JP2023544410A (ja) * 2020-10-05 2023-10-23 ブリストル－マイヤーズ スクイブ カンパニー タンパク質を濃縮するための方法
CA3199735A1 (fr) 2020-11-23 2022-05-27 Chris Klopp Systemes, composants et procedes de filtration
CN114014929B (zh) * 2021-11-04 2022-07-19 江苏荃信生物医药股份有限公司 一种抗人白介素-33单克隆抗体浓缩溶液的制备方法
TW202342068A (zh) 2022-02-25 2023-11-01 美商安進公司 製備高濃度液體原料藥之方法
CN115261193A (zh) * 2022-05-31 2022-11-01 利穗科技(苏州)有限公司 一种生物制品浓缩***及其工艺
WO2024012364A1 (fr) * 2022-07-12 2024-01-18 Beigene Switzerland Gmbh Procédés de préparation d'une solution d'anticorps pd1 hautement concentrée par ultrafiltration/diafiltration (uf/df)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5625616B2 (fr) 1973-10-08 1981-06-13
FR2459619B1 (fr) 1979-06-26 1983-07-29 Agronomique Inst Nat Rech Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede
US4374763A (en) 1979-09-17 1983-02-22 Morishita Pharmaceutical Co., Ltd. Method for producing gamma-globulin for use in intravenous administration and method for producing a pharmaceutical preparation thereof
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
ZA847349B (en) * 1983-10-05 1985-04-24 Solco Basel Ag Process for the preparation of a biologically active extract
US4786501A (en) 1985-07-15 1988-11-22 International Minerals & Chemical Corp. Cylindrical implants for the controlled release of growth hormones
US4756696A (en) 1985-12-06 1988-07-12 Amp Incorporated Solder joint inspection feature for surface mount connectors
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
JPS6485829A (en) 1987-09-29 1989-03-30 Aisin Aw Co Transmission for four-wheel drive vehicle
JPH01268646A (ja) 1988-04-20 1989-10-26 Meiji Milk Prod Co Ltd 抗腫瘍剤
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US4897465A (en) 1988-10-12 1990-01-30 Abbott Laboratories Enrichment and concentration of proteins by ultrafiltration
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
NL9001650A (nl) 1990-07-19 1992-02-17 Ver Coop Melkind Werkwijze voor de bereiding van een melkeiwit-isolaat.
WO1992003918A1 (fr) 1990-08-29 1992-03-19 Genpharm International, Inc. Animaux non humains transgeniques capables de produire des anticorps heterologues
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5256294A (en) 1990-09-17 1993-10-26 Genentech, Inc. Tangential flow filtration process and apparatus
US6582959B2 (en) 1991-03-29 2003-06-24 Genentech, Inc. Antibodies to vascular endothelial cell growth factor
JP2907603B2 (ja) * 1991-09-09 1999-06-21 雪印乳業株式会社 新規生理活性ペプチド、該活性ペプチドを有効成分とする胃酸分泌抑制剤、抗潰瘍剤及び飲食品
US6270757B1 (en) 1994-04-21 2001-08-07 Genetics Institute, Inc. Formulations for IL-11
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5707678A (en) 1995-04-12 1998-01-13 Galagen Inc. Method for microfiltration of milk or colostral whey
EP1978033A3 (fr) 1995-04-27 2008-12-24 Amgen Fremont Inc. Anticorps humains dérivés à partir de xénosouris immunisée
CA2219486A1 (fr) 1995-04-28 1996-10-31 Abgenix, Inc. Anticorps humains derives de xeno-souris immunisees
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
DE19543737A1 (de) 1995-11-24 1997-05-28 Hoechst Ag Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
CA2616914C (fr) 1996-12-03 2012-05-29 Abgenix, Inc. Anticorps de liaison de recepteur d'egf
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
JP2001516599A (ja) * 1997-09-22 2001-10-02 セプラジェン コーポレーション ホエータンパク質の逐次分離およびその配合物
RU2140287C1 (ru) 1998-08-25 1999-10-27 Государственное унитарное предприятие "Иммунопрепарат" Способ получения альбумина
WO2000024266A2 (fr) 1998-10-26 2000-05-04 Galagen, Inc. Compositions a base de soja et d'immunoglobulines
AU5719600A (en) 1999-07-07 2001-01-30 New Zealand Co-Operative Dairy Company Limited Method of obtaining protein isolates and concentrates from colostrum
JP5485489B2 (ja) * 2000-08-11 2014-05-07 中外製薬株式会社 抗体含有安定化製剤
DE60139944D1 (de) 2000-10-12 2009-10-29 Genentech Inc Niederviskose konzentrierte proteinformulierungen
ES2184594B1 (es) 2001-01-17 2004-01-01 Probitas Pharma Sa Procedimiento para la produccion de gammaglobulina g humana inactivada de virus.
WO2003042344A2 (fr) * 2001-11-13 2003-05-22 Genentech, Inc. Formulations trail/ligand apo2
NZ537687A (en) * 2002-06-21 2008-04-30 Biogen Idec Inc Buffered formulations for concentrating antibodies and methods of use thereof
EP1596667B1 (fr) * 2002-11-01 2009-01-21 Bayer HealthCare LLC Procédure pour la concentration de protéines
GB0229444D0 (en) 2002-12-18 2003-01-22 Royal Free Hampstead Nhs Trust Diagnostic method and assay kit
CA2516836A1 (fr) * 2003-02-24 2004-09-10 Gtc Biotherapeutics, Inc. Procedes de filtration tangentielle et appareil associe
JP4869064B2 (ja) 2003-04-04 2012-02-01 ジェネンテック， インコーポレイテッド 高濃度抗体及びタンパク質製剤
US20070244305A1 (en) 2004-01-30 2007-10-18 Suomen Punainen Risti Veripalvelu Process for The Manufacture of Virus Safe Immunoglobulin
US20060051347A1 (en) 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
JP6044754B2 (ja) 2012-01-19 2016-12-14 株式会社ジェイテクト クラッチプレートおよびその製造方法

Also Published As

Publication number Publication date
BRPI0515649A (pt) 2008-07-29
AR050641A1 (es) 2006-11-08
DK4108259T3 (da) 2024-03-11
HK1101249A1 (en) 2007-10-12
NO333660B1 (no) 2013-08-05
US11767370B2 (en) 2023-09-26
CN104961797B (zh) 2020-12-25
PT1786830E (pt) 2015-02-05
DK3805248T5 (da) 2023-04-24
EP4104859B1 (fr) 2024-04-17
JP5426641B2 (ja) 2014-02-26
EP4108259B1 (fr) 2024-01-03
TW200612989A (en) 2006-05-01
KR20070109975A (ko) 2007-11-15
US20060051347A1 (en) 2006-03-09
PL1786830T3 (pl) 2015-05-29
PL3805248T3 (pl) 2023-05-22
MY162525A (en) 2017-06-15
FI2292636T3 (fi) 2024-01-12
EP2292636A2 (fr) 2011-03-09
EP2292636A3 (fr) 2013-05-01
MX342788B (es) 2016-10-12
US10370456B2 (en) 2019-08-06
BRPI0515649B1 (pt) 2021-10-13
MY150549A (en) 2014-01-30
CN104961797A (zh) 2015-10-07
EP2292636B9 (fr) 2024-01-03
AU2005285243B2 (en) 2012-03-08
HK1215869A1 (zh) 2016-09-23
HUE061899T2 (hu) 2023-08-28
CN102911268A (zh) 2013-02-06
CN101056885A (zh) 2007-10-17
DK2292636T3 (da) 2024-01-15
LT2292636T (lt) 2024-01-10
RU2007110534A (ru) 2008-10-20
JP2012097086A (ja) 2012-05-24
IL216851A0 (en) 2012-01-31
SI1786830T1 (sl) 2015-03-31
ES2528541T3 (es) 2015-02-10
CA2577317A1 (fr) 2006-03-23
PL4108259T3 (pl) 2024-05-13
KR101528970B9 (ko) 2022-12-09
US20230074486A1 (en) 2023-03-09
US20140370003A1 (en) 2014-12-18
NO20071432L (no) 2007-03-16
ES2942574T3 (es) 2023-06-02
PE20060816A1 (es) 2006-09-02
WO2006031560A3 (fr) 2006-08-24
CA2577317C (fr) 2016-04-26
EP1786830B1 (fr) 2014-11-12
PT2292636T (pt) 2024-01-09
US20210095050A1 (en) 2021-04-01
KR101528970B1 (ko) 2015-06-15
LT4108259T (lt) 2024-04-10
MX2007002812A (es) 2007-05-16
FI3805248T3 (fi) 2023-04-21
EP3805248B1 (fr) 2023-01-18
WO2006031560A2 (fr) 2006-03-23
NZ553239A (en) 2009-11-27
AU2005285243A1 (en) 2006-03-23
EP4108259A1 (fr) 2022-12-28
EP2292636B1 (fr) 2023-10-18
JP5210633B2 (ja) 2013-06-12
TWI372630B (en) 2012-09-21
KR20120135530A (ko) 2012-12-14
US20090214522A1 (en) 2009-08-27
EP3805248A3 (fr) 2021-07-14
EP1786830A2 (fr) 2007-05-23
ES2968070T3 (es) 2024-05-07
AU2005285243C1 (en) 2012-10-25
ZA200701626B (en) 2008-10-29
CN101056885B (zh) 2015-08-26
SG177161A1 (en) 2012-01-30
RU2390524C2 (ru) 2010-05-27
PT3805248T (pt) 2023-04-05
EP3805248A2 (fr) 2021-04-14
GT200500254A (es) 2006-08-02
BRPI0515649B8 (pt) 2021-11-03
HUE065025T2 (hu) 2024-04-28
JP2008512473A (ja) 2008-04-24
PL2292636T3 (pl) 2024-03-11
SI4108259T1 (sl) 2024-04-30
PT4108259T (pt) 2024-03-07
SI2292636T1 (sl) 2024-02-29
IL181372A (en) 2012-01-31
IL181372A0 (en) 2007-07-04
SI3805248T1 (sl) 2023-05-31
US20070237762A1 (en) 2007-10-11
DK3805248T3 (da) 2023-04-03
DK1786830T3 (en) 2015-01-19
EP4104859A1 (fr) 2022-12-21
LT3805248T (lt) 2023-04-25
TNSN07069A1 (en) 2008-06-02
ECSP077282A (es) 2007-03-29

Similar Documents

Publication Publication Date Title
MA28991B1 (fr) Procede pour concentrer des anticorps, et produits therapeutiques correspondants
EP1839491A4 (fr) Produit laitier et procede pour le produire
FR2868414B1 (fr) Procede de production d'alpha-alumine particulaire et apha-alumine particulaire produite par ce procede
EP1928255A4 (fr) Procédé de production de produits laitiers, produits ainsi obtenus et leur utilisation
FR2944275B1 (fr) Procede pour la production de fluoroapatite, fluoroapatite et appareil d'adsorption
FR2920320B1 (fr) Procede pour la production de fluorapatite, fluorapatite et appareil d'adsorption.
IL161506A0 (en) Method for promoting sales of products
ATE311112T1 (de) Neues herstellungsverfahren für fermentierte milchprodukte
FR2869030B1 (fr) Procede de production d'alpha-alumine particulaire
HUP0402466A2 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main, intermediates of the process
HUP0402465A2 (en) Industrial process for preparing 17-hydroxy-6-betha, 7-betha, 15-betha, 16-betha-bis-methylene-3-oxo-17-alpha-pregn-4-ene-21-carboxylic acid gamma lacton and the main intermediates of the process
EP1771075A4 (fr) Produit laitier et procede de fabrication correspondant
FR2900029B1 (fr) Procede d'aromatisation de produits fromagers.
FR2869764B1 (fr) Complement nutrionnel liquide et procede de preparation de ce complement
FR2870680B1 (fr) Nouveaux produits de bonneterie et leur procede de production
NO20044969L (no) Fremgangsmate for fremstilling av fermentert produkt, og produkt fremstilt ved fremgangsmaten
NO20044967D0 (no) Fremgangsmate for fremstilling av bakteriekultur samt produkt fremstilt ved fremgangsmaten
FR2870458B1 (fr) Produits et procede pour la decontamination des prions
FI20041103A0 (fi) Menetelmä, järjestelmä ja ohjelmistotuote henkilömatkustusprosessin hallitsemiseksi
FR2871801B1 (fr) Procede de preparation d'arylboronates cycliques
UA8004S (uk) Ємність для молочних продуктів
UA11043S (uk) Пляшка для рідких продуктів